Isis Pharmaceuticals Inc. reported a significantly improved fourth quarter net income of $31 million, up from a net loss of $24.3 million in the same quarter last year.

Revenue jumped to $84.9 million for the quarter, up from $42.2 million for the same period in 2013.

Isis, a Carlsbad-based antisense drug maker, is trading on the Nasdaq under the ticker symbol ISIS. Following the earnings report Feb. 27, stock climbed 1.8 percent from $67.81 per share to $68.56.